




RealRate

PHARMACEUTICAL 2021

Y-mAbs Therapeutics Inc.
Rank 342 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Y-mAbs Therapeutics Inc. Rank 342 of 409



The relative strengths and weaknesses of Y-mAbs Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y-mAbs Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Y-mAbs Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 247% points.

The company's Economic Capital Ratio, given in the ranking table, is -467%, being 112% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	122,363
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,535
Liabilities, Non-Current	3,981
Other Assets	7,859
Other Compr. Net Income	-576
Other Expenses	2,203
Other Liabilities	2,695
Other Net Income	598
Property and Equipment	1,825
Research and Development	93,697
Revenues	20,750
Selling, General and Administrative Expense	44,785

Output Variable	Value in 1000 USD
Assets	132,047
Liabilities	26,211
Expenses	140,685
Stockholders Equity	105,836
Net Income	-119,337
Comprehensive Net Income	-119,625
Economic Capital Ratio	-467%

